

## **Erratum: 2005-07 National Survey of Research Commercialisation (NSRC)**

The Report of the 2005-2007 NSRC mistakenly did not include data provided by the Institute for Eye Research (NSW). The Department apologises for any inconvenience caused by the omission of the Institute's data both in the printed and electronic copies of the report of the survey.

This erratum, which forms part of the 2005-07 NSRC Report and should be kept with your copy of the report, is also available electronically at <http://www.innovation.gov.au/Section/Innovation/Pages/TheNationalSurveyofResearchCommercialisation.aspx>

The data represented below and overleaf is as supplied and confirmed by the Institute. Sections of the survey for which data was not provided have not been included.

Institute for Eye Research						
Q no.	Main Question (if sub questions apply)	Main Question or Sub Question	Units/Data type	2005	2006	2007
1	Institute for Eye Research					
q2a	What was your institution's research and experimental development expenditure, as reported in the most recent Australian Bureau of Statistics (ABS) survey (ie: 31 December 200x or 30 June 200x*)?	Research and Experimental Development Expenditure	\$'000	15,422	15,442	17,935
2b		Please indicate the end date for the relevant ABS survey reporting period: "A" for 31 December 200x or "B" for 30 June 200x+1		A	A	A
q3ai	In 200x, how many full time equivalents (FTEs) were employed in or engaged by your institution in the following roles, and what was the full cost of these resources?	Dedicated commercialisation staff	FTE No.	1.7	2.2	2.2
q3aii		Dedicated commercialisation staff cost	\$'000	1,087	1,343	1,343
q3bi		Commercialisation support staff	FTE No.	1.7	2	2

q3bii		Commercialisation support staff cost	\$'000	479	502	505
q3ci		Commercialisation staff total	FTE No.	3	4	4
q3cii		Commercialisation total cost	\$'000	1,566	1,845	1,848
q4a	What did your institution spend to secure statutory protection of intellectual property rights (e.g. patents, plant breeder rights, copyright, trade marks and/or registered designs) in 200x?	Cost to secure IP protection - external fees and legal costs	\$'000	106	53	74
q4b		Cost to secure IP protection - internal fees and legal costs	\$'000	21	20	20
q5		What amount was received by your institution <b>from licensees</b> as reimbursements of expenses reported in question 4a?	\$'000	0	0	0
q6		How many invention disclosures did your institution receive in 200x?	No.	0	1	9
q7ai	How many patent and/or plant breeder rights applications were filed in 200x?	Patent and/or plant breeder rights filed - Aus	No.	1	1	3
q7aii			NewNo.	1	1	3
q7bi		Patent and/or plant breeder rights filed - USA	TotalNo.	1	1	1
q7bii			NewNo.	1	0	1
q7ci		Patent and/or plant breeder rights filed - elsewhere	TotalNo.	7	2	1
q7cii			NewNo.	6	2	1
q7di		Patent and/or plant breeder rights filed - total	TotalNo.	9	4	5
q7dii			NewNo.	8	3	5
q8a	How many of the <b>new</b> patent and/or plant breeder rights applications filed in 200x (as reported in question 7) were for each of the following:	Applications for - provisional patents	NewNo.	1	1	4
q8b		Applications for - PCT patents	NewNo.	1	0	1
q8c		Applications for - innovation patents	NewNo.	0	0	0

q8d		Applications for - other	NewNo.	6	2	0
q8e		Applications for - total	NewNo.	8	3	5
q9a	How many patents and/or plant breeder rights were issued to your institution in 200x?	in Aus	No.	0	0	0
q9b		in USA	No.	0	2	0
q9c		elsewhere	No.	1	0	1
q9d		total	No.	1	2	1
q10a	How many patents and/or plant breeder rights did your institution hold as of 31 December 200x?	patents pending	No.	40	43	47
q10b		patents issued	No.	20	22	22
q10c		total	No.	60	65	69
q11		How many patents and/or plant breeder rights were culled or allowed to lapse from your institution's holdings in 200x?	No.	1	0	0
q12a	How many Licences/Options/Assignments (LOAs) did your institution:	execute during 200x	No.	0	1	2
q12b		have active as of 31 December 200x	No.	4	4	6
q13		How many active LOAs yielded income in 200x?	No.	4	4	4
q14ai	For those active LOAs that yielded income in 200x (question 13), how many LOAs and how much income for your institution can be attributed to:	LOAs and income from running royalties	No.	4	4	4
q14aii			\$'000	7,327	10,645	9,662
q14bi		LOAs and income from cashed in equity	No.	0	0	0
q14bii			\$'000	0	0	0
q14ci		LOAs and income from other types	No.	0	0	0
q14cii			\$'000	0	0	0

q14di		LOAs and income totals	No.	4	4	4
q14dii			\$'000	7,327	10,645	9,662
q15a	Please identify the number of LOAs by income in 200x:	Income under \$10,000	No.	0	0	1
q15b		Income \$10,000 - \$50,000	No.	0	1	0
q15c		Income \$10,000 - \$200,000	No.	2	0	0
q15d		Income \$200,000 - \$500,000	No.	0	1	0
q15e		Income \$500,000 and over	No.	2	2	3
q15f		Total	No.	4	4	4
q16		In 200x, how much of the income reported in question 14dii was paid to other institutions or commercial entities?	\$'000	0	0	0
q17		Based on running royalties (question 14a), what was the estimated level of sales resulting from technologies your institution has licensed in 200x or before?	\$'000	266,436	387,091	351,345
q18ai	Did your institution participate in any capital raising for research commercialisation activities (including Initial Public Offerings – IPOs) in 200x?	Capital raising - IPOs	No.	0	0	0
q18aii			\$'000	0	0	0
q18bi		Capital raising - other	No.	0	0	0
q18bii			\$'000	0	0	0
q18ci		Capital raising - total	No.	0	0	0
q18cii			\$'000	0	0	0
q19	What was the value of all research commercialisation equity holdings as of 31 December 200x?	Value of all equity holdings	\$'000	0	0	0

q20	How many start-up companies that were operational as of 31 December 200x were dependent upon the licensing/assignment of your institution's technology for initiation?	Start-up companies operational dependent on licensing/ assignment of technologies (out of Start-up companies created in the five years proceeding the reporting date)	No.	0	0	0
q21		In how many of the start-up companies operational at 31 December 200x identified in question 20 did your institution hold equity?	No.	0	0	0
q22		Please provide details ( <b>in sheet 2</b> ) for each of the start-up companies that were formed in 200x, to allow for survey follow-up if required.		0	0	0
q23a	For research consultancies and contracts your institution entered into in 200x please identify the:	No. of contracts and consultancies entered into	No.	47	40	36
q23b		Total gross contracted value	\$'000	9,507	10,435	14,425
q24a	Of those research consultancies and contracts shown in question 23, please identify the number of research consultancies and contracts according to total gross contracted value:	Gross contracted value \$0-\$10,000	No.	11	7	5
q24b		Gross contracted value \$10,000 - \$50,000	No.	12	15	8
q24c		Gross contracted value \$50,000-\$200,000	No.	19	11	15
q24d		Gross contracted value \$200,000-\$500,000	No.	1	3	4
q24e		Gross contracted value >\$500,000	No.	4	4	4
q24f		Gross contracted value total	No.	47	40	36
q26a	Does your institution offer training to its researchers and/or research students in commercialisation and entrepreneurship:	Training offered in research commercialisation (note data input masks used)	yes	yes	yes	yes
q26b	Does this training include in-house training?	In-house training provided (note data input mask used)	Yes	Yes	Yes	Yes
q26b		No. In-house training participants	No.	5	1	5

q26c	Does this training include delivery by an external provider?	Delivery by an external provider (note data input mask used)	Yes	Yes	Yes	Yes
q26c		No. External training participants	No			
q27a	Does your institution offer training to industry or other organisations to assist them in understanding research findings and/or their implications?	Training offered to industry to assist in understanding research findings (note data input mask used)	No	Yes	Yes	Yes
q27b		Please list ( <u>in sheet 3</u> ) the courses or programs available		See Sheet 3	See Sheet 3	See Sheet 3
q27c	How many participants completed these training programs in 200x?	Number of participants who completed training programmes	No.	28	28	28